Contact this trialFirst, we need to learn more about you.
Opioid Antagonist
Low-Dose Naltrexone for Post-COVID Fatigue Syndrome
Recruiting2 awardsPhase 2
Vancouver, British Columbia
This trial will study whether low-dose naltrexone can help with symptoms of Post-COVID-19 Fatigue Syndrome. LDN is a medication that is given in doses of 1-4.5 mg and is safe and well-tolerated. It may help to reduce pain and inflammation and improve well-being and immune function.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.